Trafficking and Functions of Bioactive Sphingolipids: Lessons from Cells and Model Membranes

Zhou, Kecheng

2015
ABSTRACT: Ceramide and sphingosine and their phosphorylated counterparts are recognized as "bioactive sphingolipids" and modulate membrane integrity, the activity of enzymes, or act as ligands of G protein-coupled receptors. The subcellular distribution of the bioactive sphingolipids is central to their function as the same lipid can mediate diametrically opposite effects depending on its location. To ensure that these lipids are present in the right amount and in the appropriate organelles, cells employ selective lipid transport and compartmentalize sphingolipid-metabolizing enzymes to characteristic subcellular sites. Our knowledge of key mechanisms involved in sphingolipid signaling and trafficking has increased substantially in the past decades—thanks to advances in biochemical and cell biological methods. In this review, we focus on the bioactive sphingolipids and discuss how the combination of studies in cells and in model membranes have contributed to our understanding of how they behave and function in living organisms.

KEYWORDS: ceramide, sphingosine, ceramide 1-phosphate, sphingosine 1-phosphate, membrane, lipid trafficking

SUPPLEMENT: Cellular Anatomy of Lipid Traffic

Introduction

Sphingosine was first identified and described by Johann L.W. Thudichum in the late 19th century, and since then, the class of lipids containing a sphingoid backbone has grown to over 4300 known compounds currently registered in the LIPID MAPS database (http://www.lipidmaps.org/data/structure/index.html). The sphingolipids were initially considered to be mainly structural molecules serving as building blocks of cellular membranes. In the 1980s, a role of simple sphingolipids as regulators of cell signaling started to emerge following the finding that sphingosine inhibits protein kinase C (PKC) activity and later the identification of the first G protein-coupled sphingosine 1-phosphate (S1P) receptor. These findings sparked an increased interest in sphingolipid research, and several specific regulatory roles of sphingolipids on proteins and cell signaling have since been reported. There is now a large body of information regarding sphingolipid trafficking and function from model membrane in vitro and in vivo settings. Here, we review studies performed on model membranes and cells and discuss what they have taught us about the trafficking and cellular functions of ceramide, ceramide 1-phosphate (C1P), sphingosine, and S1P, which are referred to as bioactive sphingolipids.

Ceramide

Ceramide is the first sphingolipid with a bona fide sphingosine backbone to be generated in the de novo synthesis pathway and serves as a substrate for making all other sphingolipids. Ceramide drives senescence and sensitization to apoptosis, and cancer cells commonly adjust their sphingolipid metabolism such that ceramide levels are suppressed. Defective ceramide metabolism is also associated with various disease states and metabolic disorders, such as diabetes, atherosclerosis, and, most notably, Farber's disease (acid ceramidase [aCERase] deficiency), underscoring the importance of ceramide as a regulator of cellular function and physiology.

Ceramide behavior in model membranes. Ceramides consist of a fatty acid linked to the amino group of a sphingosine backbone. The length and saturation of the acyl side chain have a marked effect on ceramide behavior in cells and in model membranes. Short-chain ceramides (C2 and C6) are commonly used in cell biological experiments because they are easy to deliver to cells from the solvent. However, the physiophysical properties of these short-chain ceramides differ from that of the C16 and C24 ceramides that are more commonly found in cells. The critical micelle concentration for the C2 and C6 ceramides is in the low micromolar range, while the long-chain C16 ceramide is basically insoluble in an aqueous solution. In contrast to C16 ceramide, the short-chain ceramides may also act as detergents and solubilize phospholipid bilayers, forming mixed ceramide phospholipid micelles. The ability of lipids to move from one membrane leaflet to the other, either spontaneously or facilitated by transport...
induced membrane permeabilization was suggested by the leakage. Ceramide generated by hydrolysis of sphingomyelin (SM) is associated with increased membrane permeability to solutes. C12:1-palmitoylceramide and 14:1-palmitoylceramide did not.

The studies of model membranes have established that long-chain ceramides increase lipid order and coalesce into “platforms” when inserted into phospholipid bilayers, measured by fluorescent probe polarization and differential scanning calorimetry.8–10 The increased lipid order in phospholipid bilayer is associated with phase separation and formation of ceramide–enriched domains.11 The coalescence of ceramide–enriched domains is dependent on acyl chain length and saturation. Very short ceramides (<C8) are miscible in dimyristoyl-phosphatidylglycerol (PC) lipid layer, longer saturated ceramides (C10–C14) form flower-shaped domains, and ceramides with C16–C18 saturated acyl chains form round- and regular-shaped micrometer-sized domains.12 In addition to acyl chain length and saturation, hydrogen bonding involving the 2NH is also crucial for efficient formation of ceramide-rich domains in fluid phosphatidylcholine bilayers.13 Ceramide-rich platforms in cells have been implicated in receptor clustering and activation at the plasma membrane and in coordinating cellular signaling events.14–17

In mammals, the most common sphingoid base is C18:1, but relatively high amounts of C20:1 and C16:1 bases can be expressed in specific cell types. The length of the sphingoid base in ceramide also affects the biophysical properties of the membranes. In a model membrane composed of palmitoyl oleoyl phosphocholine, palmitoylsphingomyelin, and cholesterol, palmitoylceramides with 16:1-, 18:1-, and 20:1–sphingoid bases induced ordered or gel phase formation, whereas the shorter C12:1-palmitoylceramide and 14:1-palmitoylceramide did not.18

The membrane-ordering effect of ceramides is also associated with increased membrane permeability to solutes. Ceramide generated by hydrolysis of sphingomyelin (SM) in vesicles induces membrane permeability and solvent leakage.19,20 A pathophysiological significance of the ceramide-induced membrane permeabilization was suggested by the finding that ceramide can induce membrane channels in mitochondria. The channels induced by ceramide in planar phospholipid membranes are up to 11 nm in diameter and stable.21 The ceramide concentration required for pore formation is within the range present in mitochondria during the induction of apoptosis,22 and ceramide can increase the permeability of mitochondrial outer membrane to cytochrome C and other small proteins.23 It has been further suggested that Bcl-2 proteins are not required for ceramide to induce channels in the mitochondrial outer membrane and that ceramide channels may be a direct mechanism for releasing proapoptotic proteins from mitochondria during apoptosis.24 Interestingly, dihydroceramide, which lacks the double bond between C4 and C5 in the sphingoid backbone, inhibits ceramide–induced channel formation in mitochondria.25 This finding is supported by the observation that ceramide but not dihydroceramide increases membrane permeability and lipid scrambling in large unilamellar vesicles.26

Model membrane studies have also been a central part of elucidating the functional properties of ceramide transfer protein (CERT), a protein that transfers ceramide from the endoplasmic reticulum (ER) to the Golgi apparatus. Using a donor–acceptor vesicle setup, CERT was found to transfer mainly ceramides with high efficiency, diacylglycerols and dihydroceramides with low efficiency, and no activity toward SM or sphingosine.27 Furthermore, CERT does not display the same transfer activity toward all ceramide species but has preference for ceramides with acyl chains of C20 or shorter.27,28

**Ceramide synthesis and trafficking.** In a cellular context, ceramide is the first sphingolipid with a complete sphingosine backbone to be formed in the de novo synthesis pathway and is the central sphingolipid from which all other sphingolipids are formed (Fig. 1). Cells utilize three pathways for generating ceramide, by removing the head group of more complex sphingolipids (eg, SM), by de novo synthesis, or via the sphingosine salvage pathway.

In cells, SM is a major source for the rapid generation of ceramide. The SM hydrolysis is carried out by sphingomyelinases, a group of phospholipase C-like enzymes, with different pH optima and subcellular localization. The sphingomyelinase family of enzymes catalyze the removal of phosphocholine head groups from SM, generating ceramide and free phosphocholine as their catalytic products. The sphingomyelinases are divided into acid, alkaline, and neutral sphingomyelinases depending on their functional pH optima.30 Alkaline sphingomyelinase is highly expressed in the intestine and liver, secreted into the intestinal lumen, and is responsible for digesting dietary SM.31 Acid sphingomyelinase (aSMase) is mainly localized to the lumen of late endosomes/lysosomes, where it degrades endocytosed SM on intraluminal vesicles.32 aSMase also exists in a secreted form, which retains its functionality at neutral pH.33 The secreted aSMase is involved in the hydrolysis of SM on the
Lessons from cells and model membranes

The release of aSMase during lysosomal exocytosis is a necessary component for resealing of wounded plasma membranes. The neutral sphingomyelinases (nSMase 1, 2, and 3) function at neutral pH, are stimulated by Mg\(^{2+}\) or Mn\(^{2+}\), and locate to the plasma membrane, Golgi and endosomes (nSMase2), nucleus (nSMase1),\(^{37}\) and ER (nSMase3).\(^{38}\) nSMase2 is the best studied of the nSMases, and its activity is stimulated by tumor necrosis factor (TNF),\(^{39,40}\) as well as cell stress, chemotherapeutic agents,\(^{41}\) and hydrogen peroxide.\(^{42}\)

Ceramide generation by nSMase2 plays a central role in the budding of intraluminal vesicles destined for secretion as exosomes.\(^{43,44}\)

The de novo synthesis of ceramide is a four-step reaction that takes place entirely in the ER. First, serine palmitoyltransferase (SPT) condensates palmitoyl-CoA and serine to produce 3-ketosphinganine. Second, 3-ketosphinganine is reduced to sphinganine, and N-acylation of sphinganine by ceramide synthases yields dihydroceramide. Finally, a double bond is introduced between C4 and C5 of dihydroceramide.
yielding ceramide. Reduced de novo sphingolipid synthesis is associated with hereditary sensory and autonomic neuropathy type I (HSAN I), an autosomal dominant inherited neurological disease characterized by loss of pain and temperature sensation and damaged autonomic functions. HSAN I patient lymphoblasts display >50% loss of SPT enzyme activity, in addition, knockout of either SPT1 or SPT2 in mice is embryonic lethal.

In the salvage pathway, ceramide is formed by direct N-acylation of sphingosine in the ER and does not require dihydroceramide desaturase. The sphingosine utilized in this pathway comes from the degradation of more complex sphingolipids and more than half of the cellular sphingolipids are estimated to be products of this pathway.

As a second messenger, a main recognized function of ceramide is mediating senescence and cell death. Ceramide is associated with both apoptotic and autophagic cell death, and several mechanistic explanations for ceramide-induced cell death have been provided. Ceramides with different acyl chain lengths can affect cell signaling differently. For instance, following B-cell receptor (BcR) triggering, C16-ceramide is the dominant species after 6 hours, while C24-ceramide becomes dominant 12–24 hours after BcR triggering. The C24-ceramide formation is required for the effector caspase activity. A study by Schiffmann et al showed that celecobox induces the expression of C16:0-Cer by activating CerS6 and the salvage pathway, which contributes to the toxic effects of celecobox. In addition, ceramides with different acyl chain lengths show different expression patterns. Koybasi et al found that, of the various ceramides, only C18:0-ceramide was selectively downregulated in head and neck cancer tissues. The endocytic trafficking of SM depends on its acyl chain length, with shorter chain length SM being preferentially recycled from early endosomal compartments, while longer chain length SM is targeted to later endosomes. Thus, part of the acyl chain-specific effects of ceramide may be due to different cellular trafficking of these lipids and their precursors.

Following its synthesis on the ER, ceramide can be transported via CERT to the Golgi for the synthesis of SM or ceramide 1-phosphate (C1P). CERT specifically extracts ceramide from phospholipid bilayers and can hold one ceramide at a time in its binding pocket. CERT is critically important for SM synthesis de novo and via the salvage pathway as loss of this transfer protein strongly reduces the production of SM. Downregulation of CERT causes a partial ceramide accumulation in the ER, induces ER stress, and sensitizes cancer cells to multiple cytotoxic agents. CERT is upregulated in many drug-resistant cell lines and in residual tumors following paclitaxel treatment of ovarian cancer, suggesting that targeting CERT might be beneficial particularly in chemotherapy-resistant cancers. Clinical investigations showed that CERT protein expression is an independent predictor of outcome in adjuvant chemotherapy-treated patients with breast cancer, by enhancing ER stress and autophagy.

Ceramide synthesized de novo in the ER may also diffuse to the mitochondria and then take part in the regulation of apoptosis. The ER and associated mitochondrial membranes are a central location for ceramide-mediated functions. High ceramide in the ER may disrupt Ca2+ homeostasis and lead to ER stress-mediated apoptosis. The ER resident SM synthase-related protein protects cells from apoptosis by converting ceramide to ceramide phosphoethanolamine, effectively lowering ER ceramide content and reducing its access to mitochondria. At mitochondria, ceramide may induce mitochondrial outer membrane permeabilization (MOMP) and cytochrome C release. This may be caused by a direct channel formation by ceramide, as suggested by model membrane studies. Interestingly, the ceramide metabolites, such as S1P and hexadecenal, have been shown to drive mitochondrial cytochrome C release and apoptosis by interaction with the proapoptotic BAX and BAK, suggesting a complex relationship between sphingolipid metabolism and MOMP. In addition to promoting mitochondria-coordinated apoptosis, ceramide can regulate autophagy and autophagic cell death from within the plasma membrane. Ceramide downregulates the amino acid transporter CD98 on the plasma membrane, inducing autophagy and ultimately starving cells to death. Ceramide has also been shown to interact with LC3B-II, directing autophagolysosomes to mitochondria, resulting in lethal mitophagy.

Considering its toxic effects, cancer cells are particularly efficient at converting ceramide to less-toxic sphingolipids, such as SM or glucosylceramide. In line with this, cancer cells have in general elevated aCERase expression compared to healthy cells.

aCERase knockout embryos do not survive beyond the two-cell stage because of apoptotic death. However, treating aCERase−/− embryos with S1P allows them to progress to the four- to eight-cell stage, suggesting a role for aCERase in providing substrate for S1P synthesis in the early stages of mammalian development. Inhibition or downregulation of aCERase sensitizes cells to apoptosis, while inhibition of aSMase has the opposite effect. It has been unclear how ceramide that is generated in the intraendosomal compartment can activate cell death pathways that are mainly coordinated from the cytosolic side. We recently reported that ceramide is not inevitably degraded in late endosomes and may exit this compartment without being subject to hydrolysis by aCERase, LAPT4M, a transmembrane protein associated with chemotherapy resistance, was found to interact with ceramide and facilitate its export from late endosomes. Interestingly, cells co-depleted of aCERase and LAPT4M were resistant to chemotherapeutic treatment, despite having substantially higher total ceramide levels than cells depleted of aCERase alone. In the aCERase/LAPT4M co-depleted cells, ceramide accumulated mainly in the late endosomal
compartment, suggesting that it did not reach the ER or mitochondria where it promotes apoptosis and chemotherapy sensitivity.

**Ceramide-1-Phosphate**

C1P has received relatively little attention compared to the other bioactive sphingolipids. C1P is involved in inflammatory signaling and immune cell trafficking. The recently identified ceramide 1-phosphate transfer protein (CPTP) is highly conserved between species and selective for C1P, which suggests that this quantitatively minor sphingolipid has an important physiological function.

**C1P in model membranes.** By using a recombinant sphingomyelinase D, which transforms SM to C1P, Stock et al. studied the effect of in situ generated C1P on model membranes. Their data showed that C1P altered the lateral structure of membranes, inducing liquid-disordered/solid-ordered domains. C1P reduces the temperature for lamellar-to-hexagonal phase transition in a mixture with phosphoethanolamine, suggesting that C1P promotes negative membrane curvature. Interestingly, C1P, in contrast to ceramide, was reported to not segregate into lateral lipid domains in phosphatidylcholine bilayers. Since the domain-forming properties of ceramide are important for receptor clustering and activation, it is conceivable that cell signaling events may be regulated by fine-tuning the relative amounts of ceramide versus C1P in membranes.

The head group of C1P has been reported to have a strong affinity for calcium ions, and C1P and Ca2+ both modulate the plasma membrane localization and activation of cytotoxic phospholipase A2 (cPLA2). Recently, a novel CPTP (previously GLTPD1) was identified. CPTP is highly specific for C1P transfer and shows no activity toward phosphatidic acid, ceramide, or complex sphingolipids. In the same study, CPTP was shown to play a central role in regulating cPLA2 activity and eicosanoid signaling.

**C1P synthesis, localization, and function.** In mammalian cells, C1P is produced in the trans-Golgi by ceramide kinase (CERK). CERK phosphorylates ceramides with acyl chain lengths from C12 to C24 with equal efficiency in vitro. In cells on the other hand, ≤C20 ceramides are preferentially used for generating C1P, and downregulation of CERT efficiently reduces cellular C1P production. This suggests that C1P synthesis by CERK is dependent on CERT-mediated ceramide transfer and that CERT preferentially transfers shorter chain ceramides in vivo as well as in vitro.

CERK is not essential for embryonic development as CERK−/− mice are fully viable developed without gross phenotypic changes. CERK-deficient mice show a significant upregulation of ceramide and downregulation of dihydroceramides in serum. The main phenotypes observed in CERK-deficient mice were defects in neutrophil homeostasis and the regulation of innate immunity. Interestingly, the cPLA2 pathways were not impaired in macrophages from CERK-deficient mice, suggesting that C1P might be compensated for by other lipid mediators. Alternatively, there may be other mechanisms generating C1P than CERK, which is suggested by the finding that C1P is present at normal levels in the brain of CERK knockout mice.

C1P stimulates arachidonic acid release in A549 cells, activates cPLA2, and enhances its interaction with phosphatidylcholine. The C1P/cPLAα interaction is required for the recruitment of cPLAα to intracellular membranes in response to inflammatory agonists. A crucial role of proper subcellular C1P localization was shown with the discovery of the CPTP. Cells depleted of CPTP had elevated levels of C1P in the trans-Golgi and reduced levels in the plasma membrane. This alteration in C1P distribution was associated with a marked increase in the release of arachidonic acid and eicosanoid generation.

C1P has also been shown to stimulate cell growth and DNA synthesis, upregulate cellular levels of proliferation cell nuclear antigen, and stimulate macrophage proliferation through activation of the PI3-kinase/Akt, JNK, and ERK1/2 pathways. C1P can inhibit aSMase in bone marrow-derived macrophages, thereby blocking caspase activation and promoting survival. Migration of immune cells from the circulation to the infected or damaged site is central to the inflammation response. C1P has also been shown to promote migration of macrophages in a pertussis toxin-sensitive manner, implicating the involvement of a G protein-coupled receptor (GPCR).

**Sphingosine**

Sphingosine is the simplest sphingolipid and is in cells generated mainly by hydrolysis of ceramide. High levels of sphingosine associate with sensitization to apoptosis and cell senescence. There are pathological states that have been in part attributed to altered levels of sphingosine. For example, patients suffering from cystic fibrosis have lowered levels of sphingosine in the airways, which makes them more susceptible to bacterial infections, and lysosomal storage phenotypes may be aggravated by sphingosine.

**Sphingosine behavior in model membranes.** One important feature of sphingosine is the amino group in the C2 position, which carries a net positive charge when protonated at low pH. As a consequence, sphingosine is membrane permeable at basic but not at acidic pH. Determination of the pKa for protonation of the amino group has yielded results ranging from 6.5 to 9.1 in a mixture with dipalmitoylphosphatidylserine. The large variations in the measured pKa is likely due to differences in sphingosine hydrogen bonding in the different mixtures. Critical micelle-forming concentrations of sphingosine are in the micromolar range, and determinations vary from 1 µM to 112 µM and are highly pH dependent. Sphingosine can increase the permeability of both model membranes and erythrocyte ghost membranes. Sphingosine-induced
channels in planar phospholipid membranes have an estimated diameter of <2 nm and had a short lifetime, whereas ceramide-induced channels that have a longer lifetime and estimated diameters of over 10 nm. In line with the respective membrane pore sizes they induce, it has been shown that ceramide, but not sphingosine, can induce the release of cytochrome C from isolated mitochondria.

**Sphingosine localization and trafficking in cells.** Sphingosine accumulates in the acidic compartments of cells due to its free amino group, which is protonated and positively charged at acidic pH. The protonated sphingosine can act as a detergent and may contribute to the apoptosis-promoting effect of sphingosine by mediating lysosomal destabilization. This type of behavior has been demonstrated under physiological conditions, where TNFα-induced sphingosine was shown to mediate lysosomal membrane permeabilization and cell death. Sphingosine is also known to potently inhibit PKC by displacing the activating lipid diacylglycerol from PKC, which contributes to sphingosine-induced cell death.

Cells from patients with Niemann-Pick’s type C or other lysosomal storage diseases often display substantial accumulation of sphingosine in acidic compartments. It has been shown that sphingosine is an early accumulant in a drug-induced Niemann-Pick’s type C and that sphingosine accentuates the disease phenotype. The reason for this sphingosine accumulation is not entirely clear but could result from defective sphingosine export from endosomes or could be due to an expanded acidic compartment that can accommodate higher amounts of sphingosine. In favor of the latter model, we have found that NPC1-depleted cells take up a larger amount of sphingosine than control cells but do not have an impaired metabolism of sphingosine to more complex sphingolipids. An enlarged acidic compartment is common in lysosomal storage disorders, and the use of fluorescent probes trapped in the acidic compartment by protonation of a primary amine has been suggested as a general indicator of lysosomal storage defects.

**Sphingosine 1-Phosphate**

In cells, S1P is the bioactive sphingolipid that has been studied the most, but it has been subject to relatively few studies in model membranes.

**S1P in model membranes.** S1P is fairly soluble in water compared to the other bioactive sphingolipids discussed here. S1P has a critical micelle-forming concentration of 12–14 µM and is likely present solubilized in the cytosol at physiologically relevant concentrations. This property of S1P may be critical for some of its described effects on soluble proteins, eg, binding to histone deacetylase (HDAC) and inhibiting its activity or to human telomerase reverse transcriptase causing its stabilization. S1P lowers the gel-to-fluid transition temperature of glycerophospholipid membranes and increases the phase transition temperature of dielaidoylphosphatidylethanolamine from lamellar to inverted hexagonal. S1P is present in cells in low concentrations, and its main effects are mediated via receptor activation or by interacting with proteins and modulating their function. Due to its low abundance, it is unlikely that S1P will have any major global effects on membrane integrity in cells.

**S1P localization and trafficking in cells.** In cells, S1P is produced by phosphorylation of sphingosine by the sphingosine kinases SK1 or SK2. S1P can also be generated by autotaxin acting on sphingosylphosphorylcholine, but the contribution of this pathway in vivo is uncertain. SK1 is a cytosolic protein and is recruited to the plasma membrane in response to, eg, growth stimulation factors such as epidermal growth factor (EGF) or phorbol 12-myristate 13-acetate. SK1 is associated with increased cell proliferation and stimulates the cell transition from G1- to S-phase. SK2, on the other hand, is mainly associated with generating S1P in the ER, and this enzyme contains a nuclear localization signal that regulates its subcellular localization dependent on PKD-mediated phosphorylation. Interestingly, SK2 expression causes cells to arrest in G1/S. The opposite effects of SK1 and SK2 on G1/S transition are dependent on enzyme localization, and targeting SK1 to the nucleus can mimic the DNA synthesis inhibitory effect of SK2.

S1P has been shown to regulate cellular functions both via intra- and extracellular mechanisms. Extracellular S1P acts on a set of GPCRs (S1P₁–S1P₅) to regulate several cell processes, including cell survival and migration. Extracellular S1P, on the other hand, was initially shown to mediate calcium release from intracellular stores, but a target ion channel has not been unequivocally identified. The most well-defined intracellular action of S1P so far is the regulation of gene transcription by binding to HDAC and inhibiting its activity. Both intra- and extracellular S1P have been associated with inflammation signaling pathways. Intracellular S1P can bind directly to TRAF2 and thereby regulate NF-kappaB activation. NF-kappaB activation may also be induced by extracellular S1P acting on GPCRs, suggesting that S1P acts upon several stages within the same signaling cascade. In the macrophage-like cell line RAW 264.7, the SK1/S1P axis was required for inflammatory signaling induced by TNFα but not by lipopolysaccharide (LPS). However, the involvement of S1P signaling in inflammatory pathways may be cell type specific or context dependent since SK1/SK2 double knockout macrophages from mice display normal inflammatory response upon treatment with LPS or TNFα. Much effort has been made to resolve the mechanisms of how S1P reaches its site of action from the site of synthesis. Due to its charged polar head group and relatively high solubility in water, S1P is unlikely to undergo spontaneous flip-flop movement in membranes and will be restricted to the compartment in which it is synthesized in the absence of transporters. Therefore, in order to act on S1P receptors from outside the cells, S1P needs to be either generated extracellularly or exported after intracellular synthesis. Both of these modes have been observed in cells. Vascular...
endothelial cells constitutively secrete SK1 in large enough quantities to generate physiologically relevant levels of extracellular S1P.\(^{23,124}\) SK1 secretion may also be regulated, as shown in monocyte U937 cells, which export cellular SK1 to the medium upon treatment with oxidized and immunocomplexed low-density lipoprotein (LDL) particles.\(^{125}\) Several studies have established that intracellularly generated S1P can also be exported to the extracellular milieu and act on S1P receptors in an auto/paracrine fashion.\(^{112,119}\) Cells depleted of the adenosine triphosphate (ATP)-binding cassette family transporters ABCC1/multidrug resistance-associated protein 1\(^{126}\) and ABCA1/cholesterol efflux regulatory protein\(^{127}\) have defective S1P release, suggesting that these transporters are involved in the release of S1P to the extracellular milieu. Interestingly, S1P is present in the circulation in sub-micromolar concentrations\(^{128,129}\) mainly in complex with high-density lipoprotein (HDL) particles,\(^{130}\) suggesting that the S1P export may be coupled with ABCA1-dependent lipoprotein formation.\(^{127}\)

Recently, a novel S1P transporter was identified by Kawahara et al.\(^{131}\) from a zebrafish mutant with a cardiac bifida phenotype resembling that of zebrafish lacking S1P\(_2\) receptor. The defective protein responsible for the phenotype was identified as Smps2.\(^{132}\) The human ortholog is a 349 aa protein with 11 predicted transmembrane helices. Smps2 does not contain an ATP-binding cassette and belongs to the major facilitator superfamily (MFS) and facilitates transmembrane movement down a chemiosmotic gradient. Smps2 activity is not strictly toward S1P but may also transport closely related molecules such as dihydro-S1P, phyto-S1P, and the S1P analog FTY720-P.\(^{132}\) Following the initial observation by the Kawahara et al, several publications in human cell models have confirmed the importance of Smps2 in regulating auto/paracrine S1P signaling.\(^{133–136}\) Mice deficient in Smps2 display early onset hearing loss and eye defects,\(^{137}\) highlighting the importance of S1P trafficking in a physiological setting. Interestingly, while mice deficient in Smps2 display a marked decrease in lymph S1P, there were no significant changes in plasma levels of S1P.\(^{138}\) Smps2-deficient red blood cells were able to phosphorylate sphingosine and secrete S1P similar to wild-type cells, suggesting that Smps2 may selectively supply S1P to lymph.\(^{138}\) The substrate-binding site in the MFS family of proteins is in the central pore formed by the transmembrane helices and does not have direct contact with the surrounding lipid bilayer.\(^{139}\) This suggests that the S1P, which is subject to transport by Smps2, is primarily the solubilized pool of S1P (estimated to be in the micromolar range\(^{108}\)) rather than the membrane-bound pool. The ligand binding to G protein coupled S1P receptors on the other hand takes place from within the membrane. The crystal structure of type 1 S1P receptor in complex with a sphingolipid mimics suggests that the agonist-binding pocket is inaccessible from the extracellular medium and that S1P reaches the binding site from within the extracellular membrane leaflet via an opening between helices I and VII of the GPCR.\(^{140}\)

**Conclusion**

Many sphingolipid metabolic pathways and their related diseases were elucidated using pure chemistry and biochemical methods in the early and middle 20th century. In the past decades, much of the research has shifted toward cell biological studies that have brought a new dimension to the field. Applying cell biology to the study of sphingolipids has its own set of challenges. Simple sphingolipids are rapidly converted into multiple metabolic products, and due to compartment-specific effects, it is critical to ensure that sphingolipid probes are targeted properly in cells. The literature contains many examples of studies that elegantly combine model membranes with cell or in vivo studies to illustrate sphingolipid behavior and function in living organisms.

**Author Contributions**

Jointly developed the structure and wrote the paper: TB and KZ. All authors reviewed and approved of the final manuscript.

**REFERENCES**


67. Zhou and Blom


